DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: ropivacaine hydrochloride

Summary for Generic Name: ropivacaine hydrochloride

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Drug Master File Entries: see list11
Suppliers: see list3
Formulation / Manufacturing:see details

Pharmacology for Ingredient: ropivacaine hydrochloride

Ingredient-typeAmides
Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia

Tentative approvals for ROPIVACAINE HYDROCHLORIDE

Applicant Application No. Form Dosage
<disabled><disabled>INJECTABLE; INJECTION2MG/ML
<disabled><disabled>INJECTABLE; INJECTION5MG/ML
<disabled><disabled>INJECTABLE; INJECTION7.5MG/ML

Clinical Trials for: ropivacaine hydrochloride

Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery
Status: Completed Condition: Laparoscopic Cholecystectomy

A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block
Status: Recruiting Condition: Upper Extremity Fracture

Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone
Status: Withdrawn Condition: Pain

Ropivacaine Hypobaric Spinal Anaesthesia in Traumatic Hip Surgery
Status: Completed Condition: Femoral Neck Fracture

Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic Surgery
Status: Completed Condition: Ovarian Cysts

A Comparison of Postoperative Analgesic Nerve Block Ropivacaine Concentrations
Status: Active, not recruiting Condition: Total Hip Arthroplasty; Postoperative Pain

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Fresenius Kabi Usa
NAROPIN
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXNo5,670,524<disabled>YYMETHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
Fresenius Kabi Usa
NAROPIN
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXNo5,834,489<disabled>YYMETHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
Fresenius Kabi Usa
NAROPIN
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXYes5,670,524<disabled>YYMETHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
Fresenius Kabi Usa
NAROPIN
ropivacaine hydrochloride
INJECTABLE;INJECTION020533Sep 24, 1996RXYes5,834,489<disabled>YYMETHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc